Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”

Research output: Contribution to journalLetterpeer-review

3 Downloads (Pure)

Abstract

We thank Auclin et al. [1] for the comments on our manuscript in Cancers titled “Value of the Lung Immune Prognostic Index (LIPI) in Patients with Non-Small Cell Lung Cancer(NSCLC) Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMpower150 Trial” [2]. We read with interest the elements of the approach proposed by Auclin et al.’s [1] to integrate LIPI into routine clinical practice and, specifically:(1) to validate LIPI retrospectively in previous clinical trials with immunotherapy; (2) to design prospective clinical trials including LIPI as a stratification factor; and (3) to design prospective clinical trials using LIPI as a marker for guiding treatment selection. However, caution is required to ensure the development of ‘host-related inflammatory indices’ for immunotherapies are well planned and target the key factors enabling precision immunotherapy use in oncology.
Original languageEnglish
Article number3763
Number of pages3
JournalCancers
Volume13
Issue number15
DOIs
Publication statusPublished - 1 Aug 2021

Keywords

  • Non-Small Cell Lung Cancer
  • Lung Immune Prognostic Index
  • First-Line Atezolizumab Combination Therapy

Fingerprint

Dive into the research topics of 'Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”'. Together they form a unique fingerprint.

Cite this